The dividend yield investors could receive from Pfizer stock has risen from about 3% in early 2022 to 7% when the market ...

This podcast was recorded on July 21, 2025. Tim Beyers: Is it time to buy biotech? You're listening to Motley Fool Money.

Keep in mind, though, that many steep dividend yields are due to the underlying stock having fallen, and Pfizer is a clear ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

In terms of fundamentals, Pfizer currently boasts a market capitalization of $132 billion. Over the last twelve months, the company generated $62 billion in revenue and sustained operational ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

Pfizer (NYSE:PFE) stock gains as the company surpasses Q2 2025 expectations with $14.7B revenue and raises its full-year ...

Global pharmaceutical company Pfizer (NYSE:PFE) announced better-than-expected revenue in Q2 CY2025, with sales up 10.3% year ...

Trump tweets trigger major stock swings for companies like Tesla, Boeing, Pfizer. Democrats demand an investigation.

Second-quarter adjusted earnings came in at 78 cents a share on revenue of $14.7 billion, beating expectations.

Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their ...

The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.